12.05.2020 • NewsCatalentDede WillamsLonza

Pfizer to Make Space for Vaccine Production

Pfizer to Make Space for Vaccine Production (c) Pfizer
Pfizer to Make Space for Vaccine Production (c) Pfizer

To save manufacturing space for its growing vaccines plans, Pfizer has said it will outsource production of some of its pharmaceutical portfolio. The work is planned to be shared out with a network of 200 contractors in the US and Europe.

The partners include major international players such as Lonza, Catalent and Thermo Fisher Scientific, Pfizer's head of global supply, Mike McDermott, told the Reuters news agency. The drugmaker didn't specify which of its contractors would be tapped in the effort.

Pfizer is also looking toward building up inventory for its drugs before starting manufacture of the potential vaccine launches at scale.

The US market’s largest player has designated three US sites and one in Belgium for the production of its Covid-19 mRNA vaccine candidate, if clinical trials are successful and regulatory approval is assured.

Pfizer is pursuing development of a vaccine in collaboration with German biotech BioNTech. The companies are now beginning human trials testing with four candidates, for which the German partner will supply doses. Earlier, Pfizer said “millions of doses” could be reader by the end of 2020, hundreds of millions in 2021.

The drugs giant’s US vaccine manufacturing sites in Kalamazoo, Michigan, and Andover, Massachusetts, as well as St. Louis, Missouri, are being eyed for the early stages of the vaccine ramp-up. Raw material manufacturing would be concentrated in St. Louis and drug substance manufacturing in Andover. Kalamazoo would handle formulation and filling.

So far, Puurs, Belgium, is the only one of Pfizer’s European manufacturing center in focus for vaccine production, but the company is said to be looking at others. BioNTech intends to add capacity at two of its facilities in Germany.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.